Parathyroid hormone levels and acute coronary events in hemodialysis patients. Fresenius Medical Care Riomar. Barranquilla, 2013-2014
DOI:
https://doi.org/10.18041/2390-0512/bioc..2.2656Keywords:
Coronary heart disease, Renal dialysis, Hemodialysis units in HospitalAbstract
Objective: To determine the levels of parathyroid hormone (PTH) and coronary events in patients undergoing hemodialysis at Fresenius Medical Care Institution Riomar in Barranquilla, during the period 2013-2014.
Materials and Methods: A descriptive and retrospective study in which 194 medical records of patients treated at the center for study institution through non probability sampling was conducted included. Scientific and methodological aspects that realize the ethical conduct during the investigation were taken into account.
Results: 60 % of patients are masculine with an average age of 59.8 years (SD +/- 16.2). 27.8 % had a coronary event and parathyroid hormone levels significantly higher (p <0.05) independently most potential confounders. However, more frequent acute coronary events in patients with PTH levels ≥ 300 pg/ml without hypertension without dyslipidemia and diabetes, aged between 60-79 years and male gender.
Conclusion: There is significant statistical association between elevated levels of parathyroid hormone and the incidence of coronary events, but prospective studies to corroborate the findings in this investigation are required
Downloads
References
2. Alan SG, Mozaffarian D, Faha PH. Heart Disease and Stroke Statistics. Circulation. 2014; 128.
3. Go AS, Mozaffarian D, Roger VL, Benjamin EJ, Berry JD, Borden WB, et al. Executive summary: heart disease and stroke statistics-2013 update: a report from the Ame-rican Heart Association. Circulation. 2013; 127:143-52.
4. Ferreira-González I. Epidemiología de la enfermedad coronaria. Rev Esp Cardiol. 2014; 67(2):139-144.
5. Organización Panamericana de la Salud. [página de Internet]. Washington: Salud en las Américas. 2007. [actualizado 20 feb 2015; citado 27 marz 2015]. Disponible en: http://www.paho.org/
6. Senior JM, Gómez C, Pardo R, Lugo L. Guía de práctica clínica para el Síndrome Coronario Agudo. Ministerio de Salud y Protección Social, Colciencias, Universidad de Antioquia. GPC-SCA; 2013.
7. Gordon T, Kannel WB, Hjortland MC, McNamara PM. Menopause and coronary heart disease. The Framingham Study. Ann Intern Med. 1978; 89:157.
8. Eknoyan G, Lameire N, Barsoum R, Eckardt KU, Levin A, Levin N, et al. The burden of kidney disease: improving global outcomes. Kidney Int. 2004; 66:1310-4.
9. Nissenson AR, Pereira BJ, Collins AJ, Steinberg EP. Prevalence and characteristics of individuals with chronic kidney disease in a large health maintenance organization. Am J Kidney Dis. 2001; 37:1177.
10. United States Renal Data System. USRDS. Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States. National Institutes of Health.National Institute of Diabetes and Digestive and Kidney Diseases. Bethesda; 2013.
11. Alabart E, Belén A, Barada C, Gustavo C, Gonzalez R, Romero A, et al. Enfermedad renal crónica: una epidemia. Revista Médica Uni-versitaria. 2009; 5(3).
12. Martínez A, Bover J. Documento consenso sobre la enfermedad renal crónica. Sociedad Española de Nefrología; 2012.
13. Minsalud. Org. [página de Internet]. Colombia: Cuenta de alto costo. Situación de la Enfermedad Renal Crónica en Colombia. 2013. [actualizado 12 feb 2015; citado 19 marz 2015]. Disponible: www.minsaludo.gov.co.
14. Sigrist MK, Taal MW, Bungay P, McIntyre CW. Progressive vascular calcification over 2 years is associated with arterial stiffening and increased mortality in patients with stages 4 and 5 chronic kidney disease. Clin J Am SocNephrol 2007; 2:1241.
Downloads
Published
Issue
Section
License
-
Reconocimiento — Debe reconocer adecuadamente la autoría, proporcionar un enlace a la licencia e indicar si se han realizado cambios<. Puede hacerlo de cualquier manera razonable, pero no de una manera que sugiera que tiene el apoyo del licenciador o lo recibe por el uso que hace.
-
NoComercial — No puede utilizar el material para una finalidad comercial.
-
CompartirIgual — Si remezcla, transforma o crea a partir del material, deberá difundir sus contribuciones bajo la misma licencia que el original.
- No hay restricciones adicionales — No puede aplicar términos legales o medidas tecnológicas que legalmente restrinjan realizar aquello que la licencia permite.
